• 1. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 2. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 3. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 4. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 5. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084

Introduction to 7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine (CAS No. 65795-37-1)

7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry due to its unique structural framework and potential biological activities. This bicyclic structure combines a pyrrole ring fused with a quinazoline moiety, featuring two amino groups at the 1 and 3 positions. The compound, identified by its Chemical Abstracts Service (CAS) number 65795-37-1, represents a promising scaffold for the development of novel therapeutic agents.

The significance of 7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine lies in its versatile pharmacophoric properties, which make it an attractive candidate for further medicinal chemistry exploration. The presence of nitrogen-rich aromatic systems suggests potential interactions with biological targets such as enzymes and receptors. Recent studies have highlighted the compound's relevance in addressing various pathological conditions by modulating key molecular pathways.

In the realm of drug discovery, the pyrrolo[3,2-f]quinazoline scaffold has been extensively studied for its ability to exhibit diverse biological effects. The fused ring system provides a rigid core that can be modified to optimize binding affinity and selectivity. Specifically, the diamine functionality at the 1 and 3 positions offers multiple sites for chemical derivatization, enabling the synthesis of a library of analogs with tailored properties.

Recent advancements in computational chemistry have facilitated the virtual screening of 7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine derivatives against large databases of biological targets. These studies have identified several lead compounds with promising activity against targets implicated in cancer, inflammation, and neurodegenerative diseases. The molecular modeling predictions have guided experimental efforts toward optimizing potency and minimizing off-target effects.

The pharmacological profile of 7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine has been preliminarily explored through in vitro assays. Initial findings indicate that certain derivatives exhibit inhibitory activity against enzymes such as kinases and phosphodiesterases, which are critical regulators of cellular signaling. Additionally, the compound demonstrates potential antimicrobial properties, making it a candidate for addressing drug-resistant infections.

The synthesis of 7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine involves multi-step organic reactions that require careful optimization to achieve high yields and purity. Common synthetic routes include cyclization reactions followed by functional group transformations to introduce the amino groups at the appropriate positions. Advances in green chemistry principles have also been applied to develop more sustainable synthetic methodologies for this scaffold.

From a medicinal chemistry perspective, the structural features of 7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine make it an ideal platform for structure-activity relationship (SAR) studies. By systematically modifying substituents on the pyrrole and quinazoline rings, researchers can elucidate key structural determinants responsible for biological activity. This approach has led to the discovery of novel compounds with enhanced pharmacological properties.

The therapeutic potential of 7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine is further supported by preclinical studies in animal models. These investigations have shown that certain derivatives exhibit favorable pharmacokinetic profiles and minimal toxicity at effective doses. The compound's ability to cross the blood-brain barrier has also raised interest in its potential applications for central nervous system disorders.

In conclusion,7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine (CAS No. 65795-37-1) represents a structurally intriguing and biologically relevant compound with broad therapeutic implications. Ongoing research continues to uncover new avenues for its development into next-generation pharmaceuticals. As our understanding of molecular mechanisms advances，this scaffold is poised to play a significant role in addressing unmet medical needs.

• 1899-48-5(Quinazoline-2,4-diamine)
• 15018-66-3(quinazolin-4-amine)
• 159382-23-7(4,6-Diaminoquinazoline)
• 1955-61-9(2,4-Quinazolinediamine,6-methyl-)
• 37521-47-4(8-methylbenzo[f]quinazoline-1,3-diamine)
• 13741-90-7(Quinazoline-2,4,6-triamine)
• 18671-95-9(6-Chloro-quinazoline-2,4-diamine)
• 63963-39-3(Benzo[h]quinazolin-4-amine)
• 27018-16-2(7-Methyl-quinazoline-2,4-diamine)
• 65796-36-3(7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine, 8-methyl-)